Hi NickE, agree with your comments in relation to recruitment and data. Imo a successful P3 trial in relation to Lupuzor would be my only concern. Tim McCarthy's statement earlier in the week gives the impression that everything is on track and news flow will be price enhancing.
I like the risk/reward here and the director purchase is a real sign of confidence but, realistically, results from phase 3 data looks like being Q1 2018 rather than Q4 2017 given recruitment is still underway. Not particularly significant but allowing for analysis of the data I don't see how they will be able to hit Q4 2017. That said, it's obviously better that they get the recruitment right rather than stress too much about being a couple of months over the current market expectation.
Thanks Jdubya, profile coverage can only be good for the company.
'"We look forward to communicating further key value enhancing newsflow during the remainder of this year and into 2017, with a focus on delivering on the key milestones for our pivotal Phase III Lupuzor trial."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.